Clinical trials: HPV InfectioN
Infections, Papillomavirus
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
The current study evaluates the immunogenicity and safety in 4-6 years old female subjects (experimental group) receiving Cervarix according to a 2-dose schedule (Month 0, 6), as compared to 4-6 years old female subjects (control…
- Trial name
- NCT01627561
- Testing
- Cervarix, Priorix, Infanrix
- Where
- 4 sites in Colombia, Mexico and 1 more
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV Seroconversion
Gardasil Immunogenicity With Needle-Free Injection
Using biospecimens collected in a trial by the Thai Red Cross AIDS Research Center that studied two new human papillomavirus (HPV) vaccine delivery regimens, the investigators at UCSF will be testing the serum for antibodies to…
- Trial name
- GINI (NCT01924754)
- Where
- 2 sites in United States, Thailand
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Wart; External Genital Organs, Condyloma Acuminata
Safety and Efficacy Study to Test Topical AS101 for External Genital Warts
The purpose of this study is to determine whether the improved topical ointment formulation, AS101, is safe and effective in the treatment of external genital warts in females.
- Trial name
- NCT01555112
- Testing
- Topical AS101
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- BioMAS Ltd
Transplantation, Systemic Lupus Erythematosus
Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy.
PRIMAVERA is a Phase IIa clinical trial, with the objective to assess the immunologic response to HPV vaccine in a population of immunocompromised girls.
- Conditions
- Transplantation, Systemic Lupus Erythematosus, Systemic Immune Disease
- Trial name
- PRIMAVERA (NCT01687192)
- Testing
- HPV prophylactic vaccine Gardasil
- Where
- 9 sites in France
- Volunteers
- 37 people
- Sponsor
- University Hospital, Bordeaux
HPV, Oropharyngeal Squamous Cell Carcinoma
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
In this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.
- Trial name
- NCT04965792
- Testing
- Screening
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dana-Farber Cancer Institute
HPV Infections
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
A study to test the safety and effectiveness of Quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against combined incidence of HPV 6/11/16/18-related persistent infection and vaccine type-specific genital disease among…
- Trial name
- NCT00834106
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 3,006 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00316693
- Testing
- HPV-16/18 vaccine (Cervarix™), Aimmugen™
- Where
- 4 sites in Japan
- Volunteers
- 1,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Decision Aid, Hpv
Patient Decision Aid Tool for HPV Vaccination Among Adults Ages 27-45 Years Old
The goal of this study is to learn if a patient decision tool for HPV vaccination works for decision-making among adults ages 27-45.
- Trial name
- HPV Decide (NCT06435338)
- Testing
- Patient decision aid, Control
- Where
- United States
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
High Risk Human Papillomavirus Infection, Low Grade Squamous Intraepithelial Lesion
Evaluation of AHCC® for the Clearance of High Risk-HPV Infections in Chinese Female
This is a multi-centre, randomised, double blind, placebo-controlled study on female participants with diagnosis of high-risk human papillomavirus (HR-HPV) infection to evaluate the clearance capacity of AHCC®.
- Trial name
- NCT04633330
- Testing
- AHCC®capsules, Simulation of AHCC®capsules
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shandong University
Verruca Vulgaris, Warts
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
- Conditions
- Verruca Vulgaris, Warts, Common Wart
- Trial name
- NCT05799157
- Testing
- VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch
- Where
- 16 sites in United States
- Volunteers
- 153 people
- Sponsor
- Veradermics, Inc.
Human Papilloma Virus, Atopic Asthma
Atopic Diseases & Human Papilloma Virus
Cervical cancer is an important health problem in women. Human papillomavirus (HPV) is considered the primary etiological agent of cervical cancer worldwide.
- Conditions
- Human Papilloma Virus, Atopic Asthma, Atopic Disorders
- Trial name
- NCT04397081
- Testing
- HPV test results
- Where
- Turkey (Türkiye)
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Adana Numune Training and Research Hospital
Human Papillomavirus Infection
Prevalence and Type Distribution of Human Papillomavirus (HPV) in Tanzanian Men
The purpose of this study is to determine the prevalence and type distribution of genital human papillomavirus (HPV) infection in Tanzanian men.
- Trial name
- NCT00932009
- Where
- Denmark
- Volunteers
- 1,933 people, healthy volunteers welcome
- Sponsor
- Danish Cancer Society
Human Papillomavirus Infection
Efficacy of Probiotic Lactobacillus Crispatus M247 in Promoting High-risk Human Papillomavirus (HR-HPV) Infection Clearance and Modifying Vaginal Microbiota
This clinical trial evaluates the efficacy of the probiotic strain Lactobacillus crispatus M247 in promoting the clearance of genital high-risk human papillomavirus (HR-HPV) infection and restoring the balance of the vaginal…
- Trial name
- NCT06802809
- Testing
- Lactobacillus crispatus M247 (Crispact®)
- Where
- 3 sites in Italy
- Volunteers
- 66 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Meningococcal Meningitis
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
The main objective is to determine whether immune responses to Tdap (GlaxoSmithKline, Boostrix®) and HPV vaccine (Merck \& Co., Inc., Gardasil®) when administered concomitantly with MenACWY are comparable to responses elicited by…
- Trial name
- NCT01424644
- Testing
- MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
- Where
- 20 sites in United States, Italy
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- Novartis
HIV Infections, Papilloma
The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women
The purpose of this study is to see how often human papillomavirus (HPV) occurs in HIV-infected women who have not taken anti-HIV drugs and to learn whether taking anti-HIV drugs will affect HPV in women.
- Trial name
- NCT00006444
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 160 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Penile Cancer, Anal Cancer
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.
- Conditions
- Penile Cancer, Anal Cancer, PIN-1, PIN-2
- Trial name
- NCT05518201
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Herpes Genitalis, Genital Wart
Safety and Efficacy of Laser Therapy in Gynaecology
The aim of this study is to retrospectively evaluate the effectiveness and safety of Er:YAG laser for treatment of different gynecological indication, e.g.
- Conditions
- Herpes Genitalis, Genital Wart, Lichen Sclerosus, Cervical Intraepithelial Neoplasia
- Trial name
- NCT04073082
- Where
- Slovenia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Juna d.o.o.
Infections, Papillomavirus
Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK
This study will assess the risk of spontaneous abortion during weeks 1-23 and weeks 1-19 of gestation, respectively, and other pregnancy outcomes, in an exposed cohort, i.e.
- Trial name
- NCT01905462
- Testing
- Data Collection, Cervarix
- Where
- United Kingdom
- Volunteers
- 1,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer Screening, HIV Infections
Anal HPV Infection and Abnormal Cytology in HIV-infected Women
The population of HIV infected women seen at Boston Medical Center may have a higher frequency of anal cytologic and histologic abnormalities than what is reported for the non-HIV infected population.
- Trial name
- NCT00933140
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Boston Medical Center
HPV Infection, Cervical Cancer
Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN
This study proposes to describe and evaluate the rate of spontaneous regression of CIN2 at 2 year of follow up in women between 18 and 39 year old.
- Trial name
- SUIVICIN (NCT04057924)
- Testing
- abstention from CIN2 treatment and surveillance for at least 2 years
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Bordeaux